ARG62480

anti-ERCC1 antibody [3H11]

anti-ERCC1 antibody [3H11] for Immunoprecipitation,Western blot and Human

Cancer antibody; Gene Regulation antibody

Overview

Product Description Mouse Monoclonal antibody [3H11] recognizes ERCC1
Tested Reactivity Hu
Tested Application IP, WB
Host Mouse
Clonality Monoclonal
Clone 3H11
Isotype IgG2a
Target Name ERCC1
Antigen Species Human
Immunogen His-tagged recombinant human ERCC1 protein.
Conjugation Un-conjugated
Alternate Names DNA excision repair protein ERCC-1; RAD10; COFS4; UV20

Application Instructions

Application Note WB: 1/375 - 1/750
IP: 2 µg/mg of lysate
* The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.

Properties

Form Liquid
Purification Protein A purified
Buffer 1X PBS buffer with <0.1% sodium azide.
Preservative <0.1% sodium azide.
Concentration 2 mg/ml
Storage Instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.
Note For laboratory research only, not for drug, diagnostic or other use.

Bioinformation

Database Links

GeneID: 2067 Human ERCC1

Swiss-port # P07992 Human DNA excision repair protein ERCC-1

Gene Symbol ERCC1
Gene Full Name excision repair cross-complementation group 1
Background The product of this gene functions in the nucleotide excision repair pathway, and is required for the repair of DNA lesions such as those induced by UV light or formed by electrophilic compounds including cisplatin. The encoded protein forms a heterodimer with the XPF endonuclease (also known as ERCC4), and the heterodimeric endonuclease catalyzes the 5' incision in the process of excising the DNA lesion. The heterodimeric endonuclease is also involved in recombinational DNA repair and in the repair of inter-strand crosslinks. Mutations in this gene result in cerebrooculofacioskeletal syndrome, and polymorphisms that alter expression of this gene may play a role in carcinogenesis. Multiple transcript variants encoding different isoforms have been found for this gene. The last exon of this gene overlaps with the CD3e molecule, epsilon associated protein gene on the opposite strand. [provided by RefSeq, Oct 2009]
Function Isoform 1: Non-catalytic component of a structure-specific DNA repair endonuclease responsible for the 5'-incision during DNA repair. Responsible, in conjunction with SLX4, for the first step in the repair of interstrand cross-links (ICL). Participates in the processing of anaphase bridge-generating DNA structures, which consist in incompletely processed DNA lesions arising during S or G2 phase, and can result in cytokinesis failure. Also required for homology-directed repair (HDR) of DNA double-strand breaks, in conjunction with SLX4. [UniProt]
Cellular Localization Nucleus
Research Area Cancer antibody; Gene Regulation antibody
Calculated MW 33 kDa

Clone References

Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species.

WB / Human

Todorova MI et al.
Mol Cancer Ther.,  (2010)

publication_link

 

hr_line

The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links.

WB / Human

Al-Minawi AZ et al.
Nucleic Acids Res.,  (2009)

publication_link

 

hr_line

Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using Automated QUantitative Analysis.

IHC / Human

Gustavson MD et al.
Appl Immunohistochem Mol Morphol.,  (2009)

publication_link

 

hr_line

ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.

WB / Human

Stordal B et al.
Cancer Chemother Pharmacol.,  (2009)

publication_link

 

hr_line

Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.

WB / Human

Prewett M et al.
Clin Cancer Res.,  (2007)

publication_link

 

hr_line